CTLA-4, another key immune checkpoint, functions by competing with CD28 for binding to B7 molecules (CD80/CD86) on antigen-presenting cells, thereby suppressing T cell activation.73 While CTLA-4 blockade has shown success in melanoma, its role in prostate cancer remains less well-defined. Here, CD80 is linked to prostate carcinoma.